Bio-Techne Corporation
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kim Kelderman
- Full Time Employees
- 3,000
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 614 McKinley Place N.E. Minneapolis MN United States of America 55413
- IPO Date
- Feb 9, 1989
- CIK
- 0000842023
- Website
- bio-techne.com
- Similar Companies
- Business
- Bio-Techne Corporation (NASDAQ: TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and supplies high-quality reagents, analytical instruments, and precision diagnostics for biotechnology research, clinical diagnostics, bioprocessing, and cell and gene therapy applications worldwide; the company operates through two primary segments, Protein Sciences, which provides biological reagents including cytokines, antibodies, immunoassays, cell selection kits, multicolor flow cytometry kits, multiplex assays, biologically active compounds, stem cell products, and proteomic analytical tools, and Diagnostics and Genomics, which offers diagnostic products such as advanced tissue-based in-situ hybridization assays for spatial genomic analysis and tissue biopsy, exosome-based molecular diagnostic assays, controls, calibrators, genetic and oncology kits, and clinical hematology controls; key brands encompass R&D Systems, Novus Biologicals, Tocris Bioscience, ProteinSimple, ACD, Asuragen, Lunaphore, and BiosPacific, with over 500,000 products in its catalog, 95% manufactured in-house, supporting customers in pharmaceutical, therapeutic, diagnostics, and life science industries across more than 34 global locations including subsidiaries in Europe, China, and Hong Kong. Founded in 1976 as Research and Diagnostic Systems and renamed Bio-Techne in 2014 following its 1981 incorporation, the company employs over 3,000 people and generated approximately $1.2 billion in net sales for fiscal 2024. Recent developments include a strategic distribution partnership with Spear Bio announced in July 2025 to expand access to SPEAR UltraDetect ultrasensitive immunoassays for neurology biomarkers such as pTau 231, pTau 217, GFAP, and Nf-L, following Bio-Techne's investment in Spear Bio's 2024 Series A funding; the divestiture of its Exosome Diagnostics business to Mdxhealth SA in August 2025 for $15 million plus royalties; licensing of AI-designed NovoBody Duo molecules from Monod Bio in November 2025 to enhance its recombinant protein portfolio; launch of the ProximityScope Assay on the BOND RX platform in October 2025 for spatial protein-protein interactions research; and an AI-powered spatial biology workflow collaboration with Nucleai in November 2025 for predictive biomarker discovery in melanoma patients.
Company News
INCY or TECH: Which Is the Better Value Stock Right Now?
INTURAI PROVIDES DEFENCE TECH COMPETITION RESULTS AND COMPANY UPDATE
Bio-Techne (NASDAQ:TECH) Reaches New 52-Week High – Time to Buy?
Zhibao Technology Signs Definitive Agreement to Acquire NEXSYS TECH for Planned AI Computing Infrastructure Business
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Looming Merger Shareholder Vote - AUUD, TECH, CZR and CBAN
CMB.TECH: Updates From Our Top Shipping Pick Of 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)
PRESS RELEASE: CMB.TECH announces special general meeting on 8 October 2026
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
CMB.TECH: Q2 Was Strong, But Valuation Looks Full (Downgrade)
CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript
CMB.TECH Q2 Earnings Call Highlights
CMB.TECH ANNOUNCES Q2 2026 RESULTS
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
BlackRock Inc. Buys Shares of 14,025,816 Bio-Techne Corp $TECH